ARICEPT significantly improves cognition, daily living over Reminyl in Alzheimers patients

GENEVA, SWITZERLAND (4 APRIL 2002) - Results from the first head-to-head study comparing ARICEPT (donepezil HCl tablets) and Reminyl (galantamine HBr tablets) demonstrated significantly greater improvements in cognition and activities of daily living (ADLs) in mild to moderate Alzheimer's disease (AD) patients treated with ARICEPT vs. Reminyl. ARICEPT-treated patients showed significant benefit over patients receiving Reminyl as measured by the modified 13-item Alzheimer's Disease Assessment Scale-cognitive subscale (modified ADAS-cog), achieved significant improvements on the Mini-Mental State Examination (MMSE), and had significantly greater improvements in ADLs, as measured by the Disability Assessment for Dementia (DAD) scale total score. The study was primarily designed to evaluate safety and tolerability. The first-ever presentation of these data took place at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (AAT) in Geneva, Switzerland.

"By comparing two available Alzheimer's disease medications, physicians now have clinical evidence that will help them prescribe the most appropriate treatment for their patients," said study investigator Roy Jones, MD, Research Institute for the Care of the Elderly, St Martin's Hospital, Bath, United Kingdom. "This three month study is encouraging news for mild to moderate Alzheimer's disease patients currently on ARICEPT, as well as those who have yet to initiate treatment." The 12-week, multinational (United Kingdom, Finland, Norway and Germany), head-to-head, randomized open-label study was designed primarily to evaluate the safety and tolerability of ARICEPT (n= 64) and Reminyl (n= 56) in 120 patients with possible or probable mild to moderate Alzheimer's disease. The study also investigated the effects of both treatments on cognition and ADLs, such as meal preparation and finance and correspondence. Trained raters who were blinded to study medication and trial results admin


Page: 1 2 3 4

Related medicine news :

1. First-of-its-kind study of vascular dementia patients taking ARICEPT presented at AAGP meeting
2. Vascular dementia patients taking ARICEPT show significant treatment benefits in cognition and function
3. ARICEPT better tolerated than Exelon in patients with mild to moderate Alzheimers disease
4. Moving admitted ER patients into inpatient beds faster could significantly increase hospital revenue
5. Gastrointestinal disorders are associated significantly with sleepless nights
6. Landmark survey reveals asthma in children remains significantly out of control in the United States
7. Data suggest ADDERALL XR significantly improved simulated driving in young adults with ADHD
8. Elderly cancer patients are significantly under-represented in cancer clinical trials
9. Generic anti-inflammatory causes significantly fewer GI complications than branded medications
10. Study shows weight-based REBETOL dosing in combination with PEG-INTRON significantly improves ...
11. Radiotherapy + cetuximab significantly improve disease control and survival in head and neck cancer

Post Your Comments:

(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
Breaking Medicine Technology:
Cached News: